Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novocure Limited (NASDAQ: NVCR) SEC filings page on Stock Titan provides access to the company’s official disclosures as a registrant under U.S. securities laws. Novocure is incorporated in Jersey and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37565. These filings document material events, financial performance and regulatory updates related to its Tumor Treating Fields (TTFields) oncology business.
Among the key documents available are Form 8-K current reports, which Novocure uses to announce items such as quarterly financial results, clinical trial decisions and regulatory milestones. Recent 8-K filings reference press releases on net revenues, active patient counts on TTFields therapy, and the termination of the LUNAR-4 trial, as well as regulatory approvals like Japan’s Ministry of Health, Labour and Welfare decision on Optune Lua for certain NSCLC patients.
Investors and researchers can also use this page to monitor periodic reports such as annual and quarterly filings when available, which typically include consolidated financial statements, details on research, development and clinical study expenses, and discussions of sales, marketing and general and administrative costs. These documents provide structured insight into Novocure’s TTFields-based product portfolio, including Optune Gio and Optune Lua, and the company’s spending on clinical and regulatory programs in glioblastoma, non-small cell lung cancer, mesothelioma and pancreatic cancer.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand changes in revenue, operating expenses, cash position and key clinical or regulatory disclosures. Users can also review insider and management-related filings such as Forms 3, 4 and 5 when available, to track equity transactions by directors and officers.
With real-time updates from EDGAR and AI-assisted explanations, this page serves as a focused resource for analyzing Novocure’s regulatory record, financial condition and material events that shape its TTFields oncology platform.
Novocure Limited reported modest growth in 2025 while advancing its cancer therapy portfolio. Full year net revenues reached $655.4 million, up 8%, with fourth quarter net revenues of $174.4 million, also up 8%, driven by more active patients on Tumor Treating Fields therapy.
Net loss improved to $136.2 million for 2025 and $24.5 million in the fourth quarter, with quarterly loss per share of $0.22. Adjusted EBITDA was $(16.4) million for the quarter and $(34.3) million for the year, reflecting high R&D and commercialization spending.
Novocure ended 2025 with $447.7 million in cash, cash equivalents and short-term investments and 4,620 active patients on therapy. In early 2026, the FDA approved Optune Pax for locally advanced pancreatic cancer, public payers in Czechia and British Columbia expanded Optune Gio coverage, and CMS reversed a temporary revocation of U.S. billing privileges. The company guided 2026 net revenues to $675–$705 million and Adjusted EBITDA between $(20) million and $0.
Novocure Limited reported that Medicare billing privileges for its U.S. subsidiary were temporarily revoked and then fully restored. CMS had revoked billing for the company’s products retroactive to December 17, 2025 due to an administrative issue with a triannual re-validation process, not a substantive qualification failure.
On February 24, 2026, CMS rescinded the revocation and reinstated Medicare billing privileges retroactive to December 17, 2025. Novocure states it continued serving existing and new patients throughout this period and believes there will ultimately be no impact on its ability to recognize revenue for those services.
Soleus Capital Master Fund, L.P. and affiliated entities filed an amended ownership report on NovoCure Limited. They report beneficial ownership of 8,530,665 ordinary shares, representing 7.6% of NovoCure’s ordinary shares, based on 111,981,981 shares outstanding as of October 24, 2025.
The group has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing is made on a passive basis, certifying that the securities were not acquired to change or influence control of NovoCure.
Novocure Limited announced that the U.S. FDA approved Optune Pax, a wearable Tumor Treating Fields device, for adult patients with locally advanced pancreatic cancer when used with gemcitabine and nab-paclitaxel. This is described as the first FDA‑approved treatment in nearly 30 years for this disease stage.
In the Phase 3 PANOVA‑3 trial (571 patients), Optune Pax plus chemotherapy improved median overall survival to 16.2 months versus 14.2 months in the intent‑to‑treat group and to 18.3 months versus 15.1 months in the modified per protocol group, with statistically significant hazard ratios. One‑year survival rates and time to pain progression also improved, while safety was mainly limited to expected skin reactions under the arrays and fatigue, with no device‑related deaths or unanticipated safety issues.
Novocure Limited reported that its U.S. subsidiary’s Centers for Medicare & Medicaid Services (CMS) billing privileges were revoked retroactive to December 17, 2025 due to an administrative issue with triannual re-validation, not a substantive qualification failure. The company has filed a Corrective Action Plan and expects billing to be reinstated but cannot predict the timing or final outcome. During the suspension, Novocure continues treating existing and new patients but cannot bill Medicare, Medicare Advantage and other CMS-related programs, and estimates it cannot recognize approximately $13 million per month in revenue from these payors. The company intends to bill for services provided once privileges are restored but cannot estimate how much, if any, will ultimately be recoverable.
NovoCure Ltd’s Chief Operating Officer, Paravasthu Mukund, reported an automatic share withholding related to equity compensation. On 01/11/2026, 2,133 ordinary shares were withheld by the company at a price of $14.35 per share to cover tax obligations arising from the vesting of Restricted Stock Units.
After this non-discretionary tax-withholding transaction, Mukund beneficially owns 78,306 ordinary shares directly. The withholding was approved as required under Rules 16b-3(e) and 16b-3(d)(1), and reflects routine tax handling of vested stock-based awards rather than an open-market sale.
NovoCure Limited filed a current report to disclose that on January 12, 2026 it issued a press release with certain preliminary financial results and other information for the quarter and year ended December 31, 2025. The report explains that the figures in the press release are unaudited, preliminary, based on the company’s good faith estimates, and remain subject to completion of its financial closing procedures and final adjustments, so actual results may differ materially. The press release is furnished as Exhibit 99.1 and the company specifies that this information is being furnished under the securities laws rather than filed for liability purposes.
NovoCure Ltd. (NVCR) reported an insider transaction on Form 4 for its Chief Financial Officer. On 11/04/2025, 7,033 ordinary shares were withheld at $12.23 to satisfy tax obligations from the vesting of Restricted Stock Units. Following this withholding (transaction code F), the CFO directly holds 134,117 shares. The filing notes the action was not discretionary and was approved pursuant to Rules 16b-3(e) and 16b-3(d)(1).
NovoCure Ltd. (NVCR) reported insider activity by Chief Operating Officer Mukund Paravasthu related to RSU vesting tax withholding. On 11/01/2025, the issuer withheld 168 ordinary shares at $12.81 per share. On 11/04/2025, the issuer withheld an additional 2,949 ordinary shares at $12.23 per share. These are coded “F” transactions, reflecting shares withheld to satisfy tax obligations and described as non-discretionary. Following these transactions, Paravasthu directly beneficially owned 80,439 ordinary shares.
NovoCure Ltd (NVCR) reported an insider transaction on a Form 4. The company’s officer, EVP, President, Novocure Oncology, had 966 ordinary shares withheld on 11/01/2025 at $12.81 per share to satisfy tax obligations upon the vesting of Restricted Stock Units (transaction code F).
Following this non-discretionary withholding, the officer beneficially owns 347,745 shares, held directly. The filing indicates it was made by one reporting person.